Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The presence of nodal metastasis is one of the most important predictive factors for recurrence after radical surgery for nonfunctioning Pancreatic Neuroendocrine Neoplasms (NF-PanNEN). Nevertheless, it is not clear which is the best diagnostic examination to identify preoperatively lymphnodal metastasis.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Giannone F
Authors: Giannone F, Muffatti F, Partelli S, Andreasi V, Guarneri G,
Keywords: imaging, lymph node, metastases,
Introduction: The annual incidence of pancreatic neuroendocrine tumours (PanNET) has been estimated to be around 0.8/100,000 inhabitants.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Giannone F
Authors: Giannone F, Partelli S, Muffatti F, Balzano G, Crippa S,
Keywords: incidentaloma, microadenoma,
Introduction: Specific biomarkers for predicting response and risk of recurrence after surgery for enteropancreatic neuroendocrine tumours (EP-NETs) are still lacking.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Partelli S
Authors: Partelli S, Kidd M, Muffatti F, Andreasi V, Giannone F,
Keywords: NETest, biomarker, Enteropancreatic Neuroendocrine Tumors, diagnosis, surgery,
Introduction: Tumor growth and Ki67 value increase are associated with aggressiveness in nonfunctioning pancreatic neuroendocrine tumours (NF-PanNET), but their natural history is largely unknown. It is unknown if the evolution of NF-PanNET is time-dependant.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Muffatti F
Authors: Muffatti F, Partelli S, Rancoita P, Andreasi V, Giannone F,
Keywords: NF-PanNET, tumor size, age, Ki-67,
Introduction: The somatostatin analog (SSA) pasireotide long-acting release (pasireotide LAR) is under investigation for the treatment of patients (pts) with NET and carcinoid disease refractory or resistant to available SSA.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author: Wolin E
Authors: Wolin E, Giannone V, Hermasillo Resendiz K,
Keywords: somatostatin analog, pasireotide, carcinoid syndrome,